Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 18;7(1):00341-2020.
doi: 10.1183/23120541.00341-2020. eCollection 2021 Jan.

The six million dollar man

Mathilde Volpato  1 , Stefan Nowak  1 , Jean Luc Bourrain  1 , Pascal Demoly  1 , Engi Ahmed  1 , Arnaud Bourdin  1 , Jeremy Charriot  1
Affiliations

The six million dollar man

Mathilde Volpato et al. ERJ Open Res. .

Abstract

In this case report, relapse of urticaria after a switch from oma- to mepolizumab successfully led to combination of biologics https://bit.ly/2GykNtI.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: M. Volpato has nothing to disclose. Conflict of interest: S. Nowak has nothing to disclose. Conflict of interest: J.L. Bourrain has nothing to disclose. Conflict of interest: P. Demoly reports grants from Stallergène Greer, ALK, AstraZeneca, Bausch & Lomb and Thermo Fisher Scientific, and personal fees from Sanofi, outside the submitted work. Conflict of interest: E. Ahmed has nothing to disclose. Conflict of interest: A. Bourdin reports grants, personal fees, nonfinancial support and other from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis; personal fees and nonfinancial support from Teva; personal fees, nonfinancial support and other from Regeneron and Chiesi Pharmaceuticals; grants, personal fees, nonfinancial support and other from Actelion; personal fees from Gilead; nonfinancial support and other from Roche; and other from Nuvaira, all outside the submitted work. Conflict of interest: J. Charriot has nothing to disclose.

Figures

FIGURE 1
FIGURE 1
At a glance: clinical and therapeutic vignette.
See this image and copyright information in PMC

References

    1. Bousquet J, Brusselle G, Buhl R, et al. . Care pathways for the selection of a biologic in severe asthma. Eur Respir J 2017; 50: 1701782. - PubMed
    1. Zuberbier T, Aberer W, Asero R, et al. . The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018; 73: 1393–1414. - PubMed
    1. Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J Allergy Clin Immunol Pract 2019; 7: 1659–1661. - PubMed
    1. Castro M, Corren J, Pavord ID, et al. . Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018; 378: 2486–2496. - PubMed
    1. Rabe KF, Nair P, Brusselle G, et al. . Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018; 378: 2475–2485. - PubMed

LinkOut - more resources